Search

everythinglearnresearchcommunity

for

Search:↓

Blocking TYK2 might be a new way to treat hair loss from alopecia areata.

Baricitinib, a drug for rheumatoid arthritis, atopic dermatitis, and alopecia areata, is generally safe with low risk of major side effects, even in patients with risk factors. It's also effective in promoting hair regrowth in alopecia areata patients.

INTASYL is a promising, adaptable RNAi technology for treating skin cancers.

Baricitinib helped a woman with severe hair loss regrow almost all her hair without side effects.

ZD1839 (Iressa) causes skin and hair side effects, treatable with tretinoin cream and minocycline.

Comprehensive screening for infections is crucial before starting JAK inhibitors in alopecia areata patients.

Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.

Human stem cells were turned into cells similar to those that help grow hair and showed potential for hair follicle formation.

JAK inhibitors help hair regrowth but not fully effective for androgenetic alopecia.

A man developed skin issues from cancer medication, which improved with specific treatments.

Abrocitinib may effectively treat Lichen Planopilaris.

Upadacitinib helped regrow hair and maintain ulcerative colitis remission.

Isotretinoin effectively improved severe pityriasis rubra pilaris with complications.

Long-term use of Risperidone may be linked to a serious skin condition in bipolar patients, affecting their overall well-being.

Low-dose sorafenib can cause severe facial acne, treatable with topical medication.

Targeted cancer therapies often cause skin problems that need careful management to improve patient quality of life and treatment success.

A new drug, abrocitinib, helped a child with severe hair loss regrow hair.

Some treatments can help with a hair loss condition called alopecia areata, but none ensure lasting results; choices depend on the person, with JAK inhibitors showing promise for severe cases.

Tofacitinib is more effective than traditional treatments for severe alopecia areata in children.

ATP helps prevent skin damage from vandetanib by reducing stress.

Tyrosine kinase inhibitors for endocrine tumors often cause skin issues, requiring early management and treatment adjustments.

Two existing drugs may help treat COVID-19 by inhibiting a key viral protein.

Antiretrovirals can affect finasteride's effectiveness, so dose adjustments may be needed for men on HIV treatment.

Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.

SGK1 is important in cancer growth and treatment resistance, and targeting it could improve therapies.

5-alpha-reductase inhibitors can lower prostate cancer risk but may increase high-grade tumors and cause sexual side effects.

Certain KIR genes in Indian SLE patients are linked to disease severity and could be biomarkers.

Janus kinase inhibitors can help children with alopecia areata regrow hair but may have some risks.

MK-386 reduces sebum DHT levels.

Rebamipide may help regrow hair by activating hair follicle stem cells.